New drug corresponding disease

Showing 49–60 of 201 results

  • Multiple sclerosis , Idiopathic pulmonary fibrosis

    Pirfenidone

    【Product name】Pirfenex, Esbriet

    [English common name]Pirfenidone

    [Chinese common name]Pirfenidone

    [English name]

    [Chinese other name]

    [indications]
    1. Idiopathic pulmonary fibrosistranssexual
    Idio-pathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease with unknown causes, poor prognosis, and high mortality. PFD is an anti-inflammatory, anti-fibrotic preparation that can be used in the treatment of IPF.
    2. Liver fibrosis
    3. Renal fibrosis
    4.Multiple sclerosis
    Multiple sclerosis (MS) is an inflammation and demyelinating disease associated with the central nervous system and immunity. The immune factors associated with it are the activation of stellate cells, glia cells, endothelial cells and the increase of lymphocytes, while PFD has the property of inhibiting cell activation.
    5. Myocardial tissue fibrosis
    Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can cause fibrosis of myocardial tissue, which in turn can worsen or develop the disease. Treatment of progressive pseudohypertrophic muscular dystrophy with PFDcardiac diseaseIt can inhibit myocardial fibrosis and improve heart function. PFD reduces myocardial remodeling and atrial fibrillation by inhibiting fibrosis.
    6. Neoplastic diseases:Neurofibroma, uterine leiomyoma, malignant glioma.
    7. Prevention of fibrosis after organ transplantation
    8.Rheumatoid arthritis

    [Usage and Dosage] This product gradually increases the dosage according to the principle of increasing dose. When taking this product on an empty stomach, the concentration of pirfenidone in the blood will increase significantly, and side effects may occur, so it is appropriate to take it after meals. The initial dosage of this product is 200mg each time, 3 times a day. It is hoped that by increasing the dose of 200mg every time in two weeks, the dosage of this product will be maintained at 600mg (1800mg per day); it should be closely observed. Patients with medication tolerance, if there are obvious gastrointestinal symptoms, skin reactions to sunlight or UV light, significant changes in liver function enzymes and weight loss, you can reduce the dose according to clinical symptoms or stop taking the drug, in the symptoms After the reduction, the dosage can be gradually increased, and it is preferable to adjust the maintenance amount to 400 mg (1200 mg per day) or more.

    [Storage] Store at 15-30 ° C; (59-86 ° F).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • epilepsy

    Zonisamide

    【Product name】Zonegran

    [English common name]Zonisamide

    [Chinese common name]Zonisamide

    [English name]Ad-810, exceglan

    [Chinese other name]1,2- benzoisoxazole-3-methanesulfonamide, oxalisulfonamide

    [indications]For each typeepilepsyAuxiliary treatment.

    【Dosage】
    1. Adults start oral administration of 100 to 200 mg per day, divided into 1 to 3 servings, and can be added to 200 to 400 mg per day for 1 to 2 weeks, with a maximum dose of 600 mg per day.
    2. Children start 2 ~ 4mg / kg per day, divided into 1 ~ 3 times, 1 ~ 2 weeks can be added to 4 ~ 8mg / kg per day, the maximum dose of 12mg / kg per day.

    [Storage] shading, sealed, and placed in a cool place (not more than 20 ° C).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Multiple myeloma

    Zoledronic acid

    【Product name】Zoledronic, RECLAST, ZOMETA

    [English common name]Zoledronic

    [Chinese common name]Zoledronic acid

    [English name]

    [Chinese other name]

    [Indications] in combination with standard anti-tumor drug therapy for the treatment of patients with solid tumor bone metastases andMultiple myelomaThe patient's bone damage. It is used to treat hypercalcemia (HCM) caused by malignant tumors.

    [Usage and Dosage] This product should not be used in combination with an infusion solution containing calcium or other divalent cations (such as lactated Ringer's solution). A single intravenous infusion should be performed using an infusion tube separate from other drugs.
    Adult and elderly
    The recommended dose is 4 mg. Dilute with 100 ml of 0.9% sodium chloride or 5% dextrose solution for an intravenous infusion of not less than 15 minutes (see [Precautions]).
    For patients with HCM (albumin-corrected serum calcium ≥ 3.0 mmol/l or 12 mg/dl), a single infusion should be accepted. Albumin-corrected serum calcium (mg/dL) = patient serum calcium (mg/dL) + 0.8 x [median serum albumin (g/L) - patient serum albumin (g/L)].
    There is limited experience with re-treatment of hypercalcemia. Re-treatment must be at least 7-10 days apart from the previous one, and serum creatinine levels should be monitored before treatment.
    The hydration status of the patient must be tested prior to administration and should be administered according to the clinical condition of the patient.
    For patients with bone metastases and multiple myeloma, this product should be given every 3-4 weeks. In addition, patients should take 500 mg of calcium and 400 IU of vitamin D daily.
    Renal insufficiency
    HCM
    For patients with HCM with severe renal impairment, the risk-benefit ratio needs to be assessed before considering the use of this product for treatment. In previous clinical trials, patients with serum creatinine >400 umol/l or >4.5 mg/dl were not enrolled. HCM patients with serum creatinine <400umol/l or <4.5mg/dl do not need to adjust the dose.
    Patient who has developed bone metastasis
    For patients with multiple myeloma and solid tumors that have undergone bone metastases, serum creatinine and creatinine clearance (CrCl) are measured at the start of treatment with this product. The CrCl value was calculated from the serum creatinine concentration value using the Cockcroft-Gault formula. Before using Zetai drugs for treatment, if the patient has developed severe renal insufficiency symptoms (CrCl<30ml/min), it is recommended to give Zetai drugs according to the following dosages (see [Precautions]): CrCl>60ml /min: 4.0 mg; CrCl 50-60 ml/min: 3.5 mg; CrCl40-49 ml/min: 3.3 mg; CrCl30-39 ml/min: 3.0 mg.
    This dose was calculated based on the assumed AUS target value of 0.66 (mgxhr/l) (CrCl = 75 ml/min). The purpose of using this dose reduction method is to achieve the same AUC value for patients with renal insufficiency as patients with creatinine clearance of 75 ml/min.
    After starting the medication, the serum creatinine concentration of the patient is measured before each administration of the product. Once the patient's renal function is found to be deteriorating, medication withdrawal is required. In clinical trials, the definition of deterioration of renal function is this:
    Serum creatinine concentrations increased from baseline normal (dl) to ≥0.5 mg/dl; and serum creatinine concentrations increased from baseline outliers (>1.4 mg/dl) to >1.0 mg/dl.
    In clinical studies, treatment of this product is continued only when creatinine levels are restored to within 10% of the baseline value (see [Precautions]). The dose of drug used to re-use Zetai should be the dose of the drug used in the previous treatment interruption.
    Hepatic insufficiency
    Because of the limited clinical data on patients with severe hepatic insufficiency, there are no specific recommendations for such patients.
    Child medication
    The safety and effectiveness of this product for children and adolescents has not yet been established.

    [Storage]Store below 30 °C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Chronic obstructive pulmonary disease (COPD)

    Tiotropium bromide

    【Product name】Spiriva

    [English common name]Tiotropium bromide

    [Chinese common name]Tiotropium bromide

    [English name]Monohydrate Capsules

    [Chinese other name]

    [indications]COPD
    Tiotropium bromide is indicated to maintain bronchodilator treatment to alleviateChronic obstructive pulmonary disease (COPD)The symptoms of the patient.
    asthma
    Spiriva Respimat is an additional maintenance bronchodilator for adults with asthma and is currently treated with a combination of inhaled corticosteroids (≥800 μg budesonide/day or equivalent) and a long-acting beta 2 agonist for treatment last year. Serious deterioration.

    【Dosage】Medicinal products are for inhalation only.The cartridge can only be used in a Respimat inhaler. Two sprays from the Respimat inhaler included a drug dose.
    The recommended dose for adults is 5 micrograms of tiotropium bromide, once daily, once a day from the Respimat inhaler.
    The recommended dose should not be exceeded.
    In the treatment of asthma, the full benefit will be apparent after a few doses of the drug.
    Special population
    Older patients can recommend a dose of tiotropium bromide.
    The recommended dose of tiotropium bromide can be used in patients with renal insufficiency. For patients with moderate to severe injury (creatinine clearance ≤ 50ml / min.)
    Patients with liver disease can recommend a dose of tiotropium bromide.
    Pediatric population
    COPD
    Spiriva Respimat has no relevant use in children and adolescents under the age of 18.
    Cystic fibrosis
    The efficacy and safety of Spiriva Respimat has not been determined.
    asthma
    The efficacy and safety of Spiriva Respimat in children and adolescents has not been determined.

    [Storage]Do not freeze.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Type 2 diabetes

    Detemir

    【Product name】Levemir

    [English common name]Insulin detemir

    [Chinese common name]Detemir

    [English name]NN 304

    [Chinese other name]Peace

    [indications]
    1. For the treatment of type 1 diabetes in adults and children.
    2. Also available forType 2 diabetesPatients supplemented with long-acting insulin to control their hyperglycemia.

    [Usage and dosage] Subcutaneous injection, 1 or 2 times a day, the dose depends on the blood sugar concentration. Oral hypoglycemic drugs can not control type 2 diabetes, if the patient has not used insulin therapy, the initial dose of this product is 0.1 ~ 0.2U / kg, once a day, or 10U each time, 1 or 2 times a day. Dosage conversion is available for patients with type 1 and type 2 diabetes who are receiving general insulin therapy when switching to this product.

    [Storage] Store at 2~8 °C to avoid freezing. The opened injection can be stored for 42 days at 30 ° C or less.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Myelodysplastic syndrome

    Decitabine

    [Product Name]DACOGEN

    [English common name] Decitabine

    [Chinese common name] Decitabine

    [English name] Decitabine intermediates

    [Chinese other name] Decitabine

    [Indications] This product ...

  • Malignant pleural mesothelioma

    Pemetrexed disodium

    【Product name】ALIMTA

    [English common name]Pemetrexed

    [Chinese common name]Pemetrexed disodium

    [English name]

    [Chinese other name]

    [indications]Malignant pleural mesotheliomaUnresectable progressive/recurrentNon-small cell lung cancer.

    [Usage and Dosage] When malignant pleural mesothelioma is combined with cisplatin, the adult usually injects 500mg/m 2 (body surface area) once a day, pemetrexed in 10 minutes, and stops for at least 20 days. Take this as a course and repeat management. In addition, weight loss is performed according to the condition of the patient.
    Unresectable progressive recurrent non-small cell lung cancer Typically, an adult is given an intravenous infusion of 500 mg/m2 (body surface area) once a day for 10 minutes for pemetrexed and discontinued for at least 20 days. In addition, weight loss is performed according to the condition of the patient.

    [Storage] This product should be stored at room temperature (15-30 ° C). The solution prepared according to the above method does not contain an antibacterial preservative, and should be used immediately from the viewpoint of microorganisms, and is not partially discarded. If it is not used up all the time, the prepared solution can be stored in the refrigerator (2-8 ° C) or at room temperature (15-30 ° C), no need to avoid light, its physical and chemical properties remain stable within 24 hours. . This product has no photosensitivity.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Growth hormone deficiency , Rare disease

    Recombinant human growth hormone

    【Product name】Ansumeng, NORDITROPIN, TEV-TROPIN, Genotropin

    [English common name]Recombinant human growth hormone

    [Chinese common name]Recombinant human growth hormone

    [English name]

    [Chinese other name]

    [Indications] This product has the same effect as human growth hormone, which can promote bone, visceral and systemic growth, promote protein synthesis, affect fat and mineral metabolism, and play a key role in human growth and development. About 80% of the subcutaneous injection was absorbed, and the peak blood concentration was reached after 5 hours, and t1/2 was about 4 hours. It is mainly used for growth disorders caused by insufficient secretion of endogenous pituitary growth hormone, dwarfism with short body, and short-term disease. In addition, it can be used to treat diseases such as burns, fractures, trauma, hemorrhagic ulcer, tissue necrosis, muscular dystrophy, and osteoporosis.

    [Usage and Dosage] The dosage of this product varies greatly. It is administered intramuscularly or subcutaneously. The dosage is 0.5-0.7 units/kg per week or 12 units/m2 per week, and it is administered 6-7 times.

    [Storage] Store at 2 ° C - 8 ° C. Valid for 1.5 years.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Rheumatoid arthritis (RA)

    Celecoxib

    [product name] Celebrex

    [English common name] Celecoxib

    [Chinese common name] celecoxib

    [English name]

    [Chinese other name]

    [indications]The potential benefits and risks of this product and other treatment options should be carefully considered before deciding to use this product. The minimum effective dose is used within the shortest treatment time, based on the treatment goals of each patient.
    (1) It is used to relieve the symptoms and signs of osteoarthritis.
    (2) for relieving adultsRheumatoid ArthritisSymptoms and signs.
    (3) for the treatment of acute pain in adults.

    [Usage and Dosage] Before deciding to use this product, you should carefully consider the potential benefits and risks of this product and other treatment options. The minimum effective dose is used within the shortest treatment time, based on the treatment goals of each patient.
    Osteoarthritis and rheumatoid arthritis, the lowest dose of this product is determined according to individual conditions. The time of eating has no effect on the dose used.
    Osteoarthritis: This product relieves the symptoms and signs of osteoarthritis. The recommended dose is 200mg, once daily or 100mg twice daily.
    Rheumatoid arthritis: This product relieves the symptoms and signs of rheumatoid arthritis. The recommended dose is 100mg to 200mg twice daily.
    Acute pain: The recommended dose is 400mg on the first day of the first dose, if necessary, can be taken 200mg; then, as needed, twice daily, 200mg each time.
    Special population
    Patients with impaired liver function: The recommended daily dose of this product should be reduced by approximately 50% in patients with moderate hepatic impairment (Child-Pugh II). This product is not recommended for patients with severe liver function impairment.

    [Storage]Sealed and stored below 25°C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Acute T cell lymphoblastic leukemia , Lymphoma

    Nairabin

    【Product name】Arranon

    [English common name]Nelarabine

    [Chinese common name]Nairabin

    [English name]Nelzarabine [USAN]

    [Chinese other name]Nairabine intermediate

    [indications]
    Nairabin injection: used to relapse or not respond to drugs after at least two chemotherapy treatmentsT cell acute lymphoblastic leukemiawithT cell lymphomapatient.
    Nairabine injection: ARRANON is a nucleoside metabolism inhibitor for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoma whose disease does not respond or recur after treatment with at least two chemotherapy regimens. This use is based on the induction of complete reactions. Randomized trials demonstrating increased survival or other clinical benefits have not been performed.

    【Dosage】
    Nairabin injection: adult recommended dose of 1500 mg / m2, intravenous infusion for 2 hours, 21 days for a course of treatment, administered on days 1, 3, 5, without dilution.
    The recommended dose for children is 650 mg/m2, intravenous infusion for 1 hour, 21 days for one course of treatment, continuous infusion for 5 days without dilution.
    Nairabine injection: Adult dose: 1,500 mg/m2, intravenously every 21 days for 2 hours on days 1, 3 and 5.
    Pediatric dose: 650 mg/m2, intravenous injection for 1 hour per day for 5 consecutive days, repeated every 21 days.

    [Storage]Store Arranon injection at 25oC (77oF); Allows offsets from 15oC to 30oC (59oF to 86oF).

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Non-small cell lung cancer (NSCLC)

    Ochinib

    【Product name】Tagrisso

    [English common name]Ochinib

    [Chinese common name]Ochinib

    [English name]

    [Chinese other name]

    [Indications] This product is suitable for the development of disease in the past or after treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), and confirmed by the detection of the presence of EGFR T790M mutation positive local late or metastasis SexNon-small cell lung cancer (NSCLC)Treatment for adult patients.

    [Usage and Dosage] This product should be used by a doctor who has experience in anti-tumor treatment.
    Before using this product to treat locally advanced or metastatic NSCLC, it is first necessary to determine the status of the EGFR T790M mutation. A well-validated test should be used to determine the presence of the EGFR T790M mutation for treatment with this product.
    dose
    The recommended dose of this product is 80mg per day until the disease progresses or the intolerable toxicity occurs.
    If you miss this product once, you should take this product, unless the next time you take the drug within 12 hours.
    This product should be taken at the same time every day, either at mealtime or on an empty stomach.
    Dose adjustment
    The medication may be suspended or reduced depending on the individual's safety and tolerability. If a reduction is required, the dose should be reduced to 40 mg once daily.
    Special population
    There is no need to adjust the dose for the patient's age, weight, sex, race and smoking status.
    Liver damage
    Mild liver function impairment (total bilirubin < upper limit of normal (ULN) and aspartate aminotransferase (AST) up to 1 to 1.5xULN; or total bilirubin up to 1 to 1.5xULN, AST is not limited) patients do not need dose adjustment, However, such patients should still use this product with caution. The safety and efficacy of this product in patients with moderate to severe liver damage is not clear. This product is not recommended for patients with moderate to severe liver damage before obtaining more information. (See [Pharmacokinetics]).
    Renal impairment
    Patients with mild to moderate renal impairment do not need to adjust the dose when using this product. There is limited data on the use of this product in patients with severe renal impairment. The safety and efficacy of end-stage renal disease (creatinine clearance (CLcr) <15 mL/min calculated by Cockcroft and Gault equations) or patients undergoing dialysis is unclear. This product should be used with caution in patients with severe or end-stage renal impairment (see [Pharmacokinetics]).
    Method of administration
    This product is for oral use. This product should be taken in whole tablets and water, and should not be crushed, cut or chewed.
    If the patient is unable to swallow the drug, the tablet can be dissolved in 50 mL of carbonate-free water. The tablets should be placed in water without crushing and stirred directly until dispersed for rapid swallowing. Then add half a cup of water to ensure no residue in the cup, then drink quickly. No other liquid should be added.
    When feeding through a gastric tube is required, the treatment can be carried out in the same manner as described above, except that 15 mL of water is initially dissolved in the drug, and 15 mL of water is used in subsequent washing of the residue. This 30 mL of fluid should be fed as directed by the nasogastric tube manufacturer and rinsed with an appropriate amount of water. These solutions and residuals should be taken within 30 minutes after the tablets are added to the water.

    [Storage]Store below 30 °C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Ovarian cancer

    Olaparib

    【Product name】Lynparza

    [English common name]Olaparib

    [Chinese common name]Olaparib

    [English name]

    [Chinese other name]

    [Indications] Platinum-based anti-tumor drugs in recurrentOvarian cancerThe sensitivity in the maintenance of treatment.

    [Usage and Dosage] Adults, twice a day, each time 300mg orally, in addition, patients with appropriate reduction in medication.

    [Storage] Do not store above 30 °C.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.